Drs. Naushira Pandya and Hady Masri share their insights into the unique risks faced by the geriatric population when it comes to RSV, in Part 2 of this Specialist Spotlight.

How common is delta 8-THC use among adolescents? Find out about this and more in today's PeerDirect Medical News Podcast.

Dr. Raagini Jawa from Boston Medical Center and the University of Pittsburgh discusses topics in office-based addiction treatment and harm reduction for indivuals with substance use disorders in this edition of the Specialist Spotlight.

Drs. Rosenberg and Morgans share their insights into some late-breaker abstracts presented at the 2024 ASCO GU symposium in San Francisco. The first is a subgroup analysis from EV‑302 with enfortumab vedotin and pembrolizumab, and the other is AMBASSADOR, which looks at adjuvant pembrolizumab in locally advanced and muscle invasive urothelial cancer.

Drs. Naushira Pandya and Hady Masri share their insights into the unique risks faced by the geriatric population when it comes to RSV.

Are generics for fingolimod as effective as the non-generic formulation? Find out about this and more in today's PV Roundup podcast.

Alison Buttenheim, PhD from PennNursing joins the podcast to talk about the behavioral aspects of infectious disease prevention and vaccine acceptance.

Drs. Rosenberg and Morgans share their insights into 2 late‑breaking abstracts presented at ESMO 2023 on the first‑line treatment of metastatic urothelial carcinoma: EV‑302 on the combination of enfortumab vedotin and pembrolizumab and CheckMate 901 on the combination of nivolumab and gemcitabine/cisplatin.

Drs. Kenneth Chinsky and Angela R. Branche share their insights into the Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults study, for which Dr. Chinsky was part of the study group and principal investigator at his clinic in Erie, PA. They discuss the findings and what they mean for HCPs who see and care for older adults who are at risk for RSV.

Annual breast cancer screening starting at age 40 provides the greatest benefit to women with the least amount of risk, according to a study published in Radiology, a study of patients with anti-citrullinated protein antibodies and subclinical inflammatory changes in joints, published in The Lancet, has shown that 6-month treatment with abatacept can improve inflammation and decrease the risk of rheumatoid arthritis, and persistent false positive COVID-19 rapid antigen tests are rare, but possible.